Thuasne is investing €4 million to develop a digital dynamic compression solution for patients suffering from post-cancer lymphedema. This project, conducted in partnership with Jean Monnet University, is part of the France 2030 programme.
This, still poorly understood, chronic condition affects approximately 200,000 people in France. To address this, the company is using its expertise, particularly its Mobiderm technology, to offer an innovative device that promotes patient autonomy and improved treatment management.
The device is based on a portable system integrating sensors, algorithms, and digital interfaces. It allows for real-time adjustment of therapeutic pressure according to the patient’s needs. The goal is to simplify an often complex care pathway, while reducing travel and improving access to treatment, including in remote areas.
Expected benefits include improved treatment practices, optimized medical time, and reduced costs for the healthcare system. Several clinical studies will evaluate the impact.
Finally, this project strengthens Thuasne’s local roots and aims for international deployment, particularly in Europe and the United States.
Website: https://corporate.thuasne.com
Funders
Our certifications
